asuragen_logo_2c_RGB

Asuragen CEO to Speak at 2017 World CDx Summit

Key industry leaders to discuss the future of precision medicine

AUSTIN, Texas–(BUSINESS WIRE)–Asuragen, Inc., a molecular diagnostics products company changing the way patients are treated in genetics and oncology by bringing complex molecular tests to hospital and reference labs, announced that its president and CEO, Matthew McManus, M.D., Ph.D., will participate in a keynote panel during the 2017 World CDx Summit taking place October 17-19 in Boston. The panel will assemble key industry leaders and stakeholders for a holistic discussion about the overarching challenges facing precision medicine and how to better align and collaborate for its success.

“There are so many stakeholders involved in shaping precision medicine, from regulatory agencies and payers to pharmaceutical and diagnostic companies,” said McManus. “Each has unique considerations that must come together in concert to advance precision medicine as a whole. This is a critical conversation facing our industry today and I’m looking forward to representing the diagnostic point of view on this panel.”

The keynote panel, titled, “Precision Medicine Under the Microscope: A Frank Look at the Impact of Precision Medicine on Patient Welfare,” will take place on Wednesday, October 18 at 10 a.m. Fellow panelists include Adam Berger, senior staff fellow, personalized medicine, FDA; Phillip Lerner, vice president & national medical director, Aetna; Jeff Allen, president & CEO, Friends of Cancer Research; and Debra Rasmussen, diagnostics leader & senior director of global regulatory affairs, Janssen Pharmaceuticals. The panel will assess the success of precision medicine efforts past and present and what stands in the way of realizing the full potential of precision medicine.

In addition to this session, Asuragen will moderate a panel discussion titled, “Precision Medicine & Companion Dx – The Evolving Role of In Vitro Diagnostics Guiding Patient Management from Risk Stratification to Outcome,” which will take place from 9 a.m. – 12 p.m. on Tuesday, October 17. The panel will host experts from across the industry providing a variety of perspectives, including: John W. Longshore, Ph.D., director of Molecular Pathology, Carolinas HealthCare System; Hannah Mamuszka, CEO, ALVA10; Peter Hoehn, J.D., global business leader, Janssen Diagnostics at Johnson & Johnson; and Matt McManus, M.D., Ph.D., president and CEO, Asuragen, Inc. The discussion will highlight the challenges and opportunities of precision medicine, review when to decentralize versus centralize testing, and will explore how to expand the scope of precision medicine across the entire patient care continuum from predisposition testing to outcomes measurement.

About Asuragen

Asuragen is a molecular diagnostic company changing the way patients are treated in genetics and oncology. The quality, simplicity and sensitivity of its products brings precision medicine within reach. Asuragen’s diagnostic systems, composed of proprietary chemistry and software, deliver powerful answers using broadly installed instrument platforms. They are simple to adopt and expand the ability to serve patients. Asuragen is a product foundry rapidly and efficiently addressing current and emerging clinical needs, including cancer diagnosis and monitoring, reproductive health and aging, serving laboratories across a patient’s lifespan with its best in class diagnostic tests. For more information, visit www.asuragen.com.

Contacts

Asuragen, Inc.
Lynne Hohlfeld, 512-681-5200
SVP, Corporate Development and CFO
lhohlfeld@asuragen.com
or
Pure Communications, Inc.
Media:
Stephanie Collins, 512-693-4873
stcollins@purecommunicationsinc.com
or
Investors:
Courtney Dugan, 212-257-6723
cdugan@purecommunications.com